Table 3.
Associations between diagnostic time periods and 5-year risk of cause-specific death stratified by chemotherapy treatment
| Five-year risk of cause-specific death, HR (95% CI)a |
||||||
|---|---|---|---|---|---|---|
| Colorectal cancer |
Circulation disorders |
Secondary cancer |
||||
| No chemo | Chemo | No chemo | Chemo | No chemo | Chemo | |
| All stages | ||||||
| 1996–2001 versus 1992–1995 | 1.04 (0.98–1.12) | 0.92 (0.86–0.97) | 0.73 (0.65–0.82) | 0.75 (0.64–0.88) | 1.58 (1.22–2.06) | 0.96 (0.74–1.25) |
| 2002–2004 versus 1992–1995 | 0.93 (0.87–1.02) | 0.76 (0.71–0.81) | 0.56 (0.50–0.63) | 0.60 (0.50–0.72) | 1.68 (1.29–2.18) | 1.46 (1.15–1.85) |
| Subgroups | Stratified analysis | |||||
| Stage II–III | ||||||
| 1996–2001 versus 1992–1995 | 1.03 (0.93–1.15) | 0.80 (0.73–0.88) | 0.81 (0.71–0.93) | 0.72 (0.59–0.89) | 1.47 (1.00–2.16) | 0.70 (0.48–1.03) |
| 2002–2004 versus 1992–1995 | 0.87 (0.79–0.96) | 0.73 (0.66–0.81) | 0.55 (0.47–0.64) | 0.65 (0.52–0.81) | 1.78 (1.24–2.56) | 1.15 (0.80–1.66) |
| Stage IV | ||||||
| 1996–2001 versus 1992–1995 | 1.13 (1.01–1.25) | 0.97 (0.88–1.08) | 1.06 (0.73–1.54) | 0.84 (0.52–1.35) | 1.03 (0.65–1.63) | 1.43 (0.84–2.44) |
| 2002–2004 versus 1992–1995 | 1.03 (0.91–1.16) | 0.86 (0.76–0.97) | 0.75 (0.48–1.17) | 0.62 (0.34–1.13) | 1.40 (0.87–2.26) | 1.08 (0.57–2.08) |
| No comorbidity, all stages | ||||||
| 1996–2001 versus 1992–1995 | 1.06 (0.98–1.16) | 0.87 (0.80–0.94) | 0.83 (0.69–0.99) | 0.52 (0.40–0.68) | 1.47 (1.03–2.11) | 1.21 (0.86–1.69) |
| 2002–2004 versus 1992–1995 | 0.90 (0.82–0.98) | 0.75 (0.68–0.82) | 0.52 (0.42–0.65) | 0.53 (0.40–0.71) | 1.91 (1.33–2.74) | 1.60 (1.14–2.23) |
| Comorbidity, all stages | ||||||
| 1996–2001 versus 1992–1995 | 1.02 (0.91–1.14) | 0.95 (0.86–1.05) | 0.69 (0.59–0.80) | 0.94 (0.76–1.15) | 1.41 (0.94–2.13) | 0.73 (0.48–1.13) |
| 2002–2004 versus 1992–1995 | 1.01 (0.91–1.12) | 0.80 (0.72–0.88) | 0.56 (0.48–0.65) | 0.62 (0.50–0.78) | 1.67 (1.14–2.44) | 1.18 (0.82–1.68) |
| No toxicity, all stages | ||||||
| 1996–2001 versus 1992–1995 | 1.06 (0.99–1.13) | 0.89 (0.84–0.95) | 0.72 (0.64–0.82) | 0.76 (0.64–0.90) | 1.41 (1.07–1.86) | 1.04 (0.79–1.37) |
| 2002–2004 versus 1992–1995 | 0.94 (0.88–1.01) | 0.77 (0.71–0.82) | 0.54 (0.48–0.62) | 0.64 (0.53–0.78) | 1.53 (1.16–2.01) | 1.46 (1.12–1.89) |
| Toxicity, all stages | ||||||
| 1996–2001 versus 1992–1995 | 0.87 (0.65–1.17) | 0.96 (0.73–1.27) | 0.89 (0.63–1.25) | 0.88 (0.50–1.55) | 0.84 (0.26–2.69) | 1.49 (0.56–3.93) |
| 2002–2004 versus 1992–1995 | 1.10 (0.85–1.44) | 0.83 (0.64–1.06) | 0.81 (0.57–1.14) | 0.68 (0.38–1.21) | 3.51 (1.43–8.59) | 1.86 (0.80–4.35) |
aChemotherapy recipients were matched with nonrecipients bases on propensity score, HR adjusted for demographics (age, gender, race, SEER regions), tumor characteristics (tumor grade, tumor stage, tumor site, no. of lymph nodes examined, no. of positive lymph nodes).